Literature DB >> 17986273

Can ID Migraine be used as a screening test for adolescent migraine?

M Zarifoğlu1, N Karli, O Taşkapilioğlu.   

Abstract

Although the ID Migraine has been developed and used for adults, it can also be used in adolescents. We aimed to investigate the validity of the ID Migraine in the adolescent student population. The study was performed on 1064 adolescents aged 12-17 years. A face-to-face semistructured interview was conducted with students after they had answered a 17-item questionnaire on sociodemographics and headache. Students who had had two or more headache attacks during the last 3 months then answered the ID Migraine. The sensitivity and specificity of the ID Migraine were 62.1% and 71.1%, respectively. The sensitivity was higher for patients with migraine with aura (71.1%), for girls (71.3%) and for younger adolescents (69.1%). The specificity was higher for boys (77.9%) and for older adolescents (73.3%). The kappa value was 0.316 (P < 0.001). Although the kappa value of the ID Migraine is low, the test may be a useful tool in screening adolescent migraine after some changes are made.

Entities:  

Mesh:

Year:  2007        PMID: 17986273     DOI: 10.1111/j.1468-2982.2007.01470.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  12 in total

1.  Comorbidity of Migraine, Major Depressive Disorder, and Generalized Anxiety Disorder in Adolescents and Young Adults.

Authors:  Lilian N Dindo; Ana Recober; Rita Haddad; Chadi A Calarge
Journal:  Int J Behav Med       Date:  2017-08

2.  The use of ID migraine™ questionnaire in patients with multiple sclerosis.

Authors:  Veronica Villani; Luca Prosperini; Carlo Pozzilli; Marco Salvetti; Alessandro Ciuffoli; Giuliano Sette
Journal:  Neurol Sci       Date:  2010-11-11       Impact factor: 3.307

3.  Prevalence of migraine headaches and their impact on the academic performance of Sudanese medical students using ID-Migraine test as a screening tool: A cross-sectional study.

Authors:  Moaid Mohamed Osman Ali; Khabab Abbasher Hussien Mohamed Ahmed; Mohammed Eltahier Abdalla Omer
Journal:  Brain Behav       Date:  2022-04-21       Impact factor: 3.405

4.  Prevalence of migraine diagnosis using ID Migraine among university students in southern Turkey.

Authors:  Sebnem Bicakci; Nafiz Bozdemir; Fahri Over; Esra Saatci; Yakup Sarica
Journal:  J Headache Pain       Date:  2008-04-22       Impact factor: 7.277

5.  Migraine prevalence, alexithymia, and post-traumatic stress disorder among medical students in Turkey.

Authors:  Hatice Balaban; Murat Semiz; Ilteriş Ahmet Şentürk; Önder Kavakçı; Ziynet Cınar; Ayfer Dikici; Suat Topaktaş
Journal:  J Headache Pain       Date:  2012-04-26       Impact factor: 7.277

6.  Association between somatic amplification, anxiety, depression, stress and migraine.

Authors:  Burcu Goksan Yavuz; Elif Ilgaz Aydinlar; Pinar Yalinay Dikmen; Cem Incesu
Journal:  J Headache Pain       Date:  2013-06-25       Impact factor: 7.277

Review 7.  Overview of diagnosis and management of paediatric headache. Part I: diagnosis.

Authors:  Aynur Ozge; Cristiano Termine; Fabio Antonaci; Sophia Natriashvili; Vincenzo Guidetti; Ciçek Wöber-Bingöl
Journal:  J Headache Pain       Date:  2011-02-27       Impact factor: 7.277

8.  Migraine headaches among university students using ID Migraine test as a screening tool.

Authors:  Serdar Oztora; Osman Korkmaz; Nezih Dagdeviren; Yahya Celik; Ayse Caylan; Mehmet S Top; Talip Asil
Journal:  BMC Neurol       Date:  2011-08-19       Impact factor: 2.474

9.  Prevalence of migraine and co-morbid psychiatric disorders among students of Cumhuriyet University.

Authors:  Murat Semiz; Ilteriş Ahmet Şentürk; Hatice Balaban; Ayşegül Kartal Yağız; Önder Kavakçı
Journal:  J Headache Pain       Date:  2013-04-11       Impact factor: 7.277

10.  Migraine among medical students in Kuwait University.

Authors:  Jasem Y Al-Hashel; Samar Farouk Ahmed; Raed Alroughani; Peter J Goadsby
Journal:  J Headache Pain       Date:  2014-05-10       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.